Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F de Groot

Showing results (101-110 of 121) with videos related to

Pageof 13
Sort By:
Oncoimmunology|July 30, 2016
Prioritization schema for immunotherapy clinical trials in glioblastomaTiffany R Hodges, Sherise D Ferguson, Hillary G Caruso, et al.
International Journal of Radiation Oncology, Biology, Physics|December 2, 2019
High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539C Leland Rogers, Minhee Won, Michael A Vogelbaum, et al.
Neuro-Oncology|March 1, 2021
A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastomaPaul D Brown, Caroline Chung, Diane D Liu, et al.
Neuro-Oncology|April 6, 2021
Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experienceEudocia Q Lee, Wendy Selig, Clair Meehan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2026
A genomically-tailored multi-agent precision medicine clinical trial for adults with recurrent glioblastomaJiaying Chen, Nancy Ann Oberheim Bush, Jennifer A Grabowsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2020
Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II TrialShiao-Pei Weathers, Marta Penas-Prado, Be-Lian Pei, et al.
Neuro-Oncology|June 3, 2022
Low-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539C Leland Rogers, Stephanie L Pugh, Michael A Vogelbaum, et al.
Neuro-Oncology|May 3, 2015
Toward precision medicine in glioblastoma: the promise and the challengesMichael D Prados, Sara A Byron, Nhan L Tran, et al.
Nature Cancer|March 19, 2026
Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2<sup>+</sup> breast cancer: TBCRC049 phase 2 study resultsRashmi K Murthy, Barbara J O'Brien, Donald A Berry, et al.
Neuro-Oncology|September 21, 2014
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastomaMarta Penas-Prado, Kenneth R Hess, Michael J Fisch, et al.
Pageof 13

Showing results (101-110 of 121) with videos related to

Sort By:
Pageof 13
Oncoimmunology|July 30, 2016
Prioritization schema for immunotherapy clinical trials in glioblastomaTiffany R Hodges, Sherise D Ferguson, Hillary G Caruso, et al.
International Journal of Radiation Oncology, Biology, Physics|December 2, 2019
High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539C Leland Rogers, Minhee Won, Michael A Vogelbaum, et al.
Neuro-Oncology|March 1, 2021
A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastomaPaul D Brown, Caroline Chung, Diane D Liu, et al.
Neuro-Oncology|April 6, 2021
Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experienceEudocia Q Lee, Wendy Selig, Clair Meehan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2026
A genomically-tailored multi-agent precision medicine clinical trial for adults with recurrent glioblastomaJiaying Chen, Nancy Ann Oberheim Bush, Jennifer A Grabowsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2020
Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II TrialShiao-Pei Weathers, Marta Penas-Prado, Be-Lian Pei, et al.
Neuro-Oncology|June 3, 2022
Low-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539C Leland Rogers, Stephanie L Pugh, Michael A Vogelbaum, et al.
Neuro-Oncology|May 3, 2015
Toward precision medicine in glioblastoma: the promise and the challengesMichael D Prados, Sara A Byron, Nhan L Tran, et al.
Nature Cancer|March 19, 2026
Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2<sup>+</sup> breast cancer: TBCRC049 phase 2 study resultsRashmi K Murthy, Barbara J O'Brien, Donald A Berry, et al.
Neuro-Oncology|September 21, 2014
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastomaMarta Penas-Prado, Kenneth R Hess, Michael J Fisch, et al.
Pageof 13